Joint Formulary & PAD

Ciclosporin - Dry eyes

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Eye drops (unit dose)
Associated Icons :
Restrictions / Comments :
Important
0.1% ciclosporin (Ikervis). For dry eye disease that has not improved despite use of tear substitutes
 

Status 2

See narrative
Formulations :
  • Eye drops (unit dose)
Associated Icons :
Restrictions / Comments :
Important

0.9mg/ml (0.09%) single use.

Not assessed for inclusion on the formulary. Contact pharmacy team for advice on making an application.

This drug has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. 

Before prescribing this drug it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.

PAD Profile

ChemicalSubstance :
Ciclosporin
Indication :
Dry eyes
Group Name :
Keywords :
Keratitis, moderate to severe dry eye
Brand Names Include :
Ikervis
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
5
Traffic Light Entries :
2